Connecticut · Public charity
The Fibrolamellar Cancer Foundation
Fibrolamellar cancer foundation,(the "foundation") was established to raise awareness and research funds for fibrolamellar carcinoma, a rare form of liver cancer that is primarily seen in teens and young adults. Currently, there are no viable treatment options other than liver resection surgery. Our mission is to find a cure and reliable…
- $1.7M
- Granted FY2024(still arriving)
- 7
- Itemized grants FY2024
- 10
- Organizations funded FY2023
- 30%
- First-time grantees FY2023
- Itemized, FY2024
- $1.4M
- The rest is grants the schedule does not break out
- Median grant, FY2024
- $199,996
- Largest grant, FY2024
- $400,000
- Organizations funded a year
- 3 to 10
- FY2017 to FY2023
- States reached, FY2024
- 3
- Total assets, FY2024
- $10M
How open it is to new grantees
In FY2023, 30% of the organizations The Fibrolamellar Cancer Foundation funded were first-time grantees, receiving 64% of its grant dollars.
New vs renewed · share of each year
In FY2023, 36% of grant dollars renewed an existing relationship; $2.6M went to new ones.
Where new relationships form · theme of each grantee’s first grant
How this is measured
The numbers by year
| Fiscal year | Organizations funded | To those organizations | First-time grantees |
|---|---|---|---|
| FY2024still arriving | 7 | $1.4M | 29% |
| FY2023 | 10 | $4.0M | 30% |
| FY2022 | 8 | $1.4M | 13% |
| FY2021 | 6 | $804k | 50% |
| FY2020 | 9 | $1.9M | 56% |
| FY2019 | 7 | $913k | 43% |
| FY2018 | 3 | $600k | 33% |
| FY2017 | 3 | $405k | n/a |
What it funded, over time
Every grant placed by its stated purpose and the recipient’s mission, by year, FY2017 to 2024.
Where its grants go
Grant dollars by states, across the years we hold.
Which US states its grants reach
Top grantees
Largest recipients by total granted, FY2017 to FY2024, and the share of each one’s budget the grants supplied at peak.
| Grantee | Total granted | Years | Share of their budget |
|---|---|---|---|
| Dracen Pharmaceuticals Inc | $2,404,179 | 1 | n/a |
| University of Washington | $2,040,000 | 7 | n/a |
| Cornell University | $1,540,212 | 7 | 0% |
| University of California San Francisco | $702,158 | 4 | n/a |
| Mass General Brigham Incorporated | $555,993 | 3 | n/a |
| Johns Hopkins University | $479,425 | 5 | 0% |
| X-Chem Inc | $400,000 | 1 | n/a |
| St Jude Children's Research Hospital Inc | $400,000 | 2 | 0% |
| Children's Hospital Medical Center | $367,814 | 2 | 0% |
| Cancer Research Institute Inc | $351,000 | 1 | 1% |
Show all 21 grantees
| Grantee | Total granted | Years | Share of their budget |
|---|---|---|---|
| Dracen Pharmaceuticals Inc | $2,404,179 | 1 | n/a |
| University of Washington | $2,040,000 | 7 | n/a |
| Cornell University | $1,540,212 | 7 | 0% |
| University of California San Francisco | $702,158 | 4 | n/a |
| Mass General Brigham Incorporated | $555,993 | 3 | n/a |
| Johns Hopkins University | $479,425 | 5 | 0% |
| X-Chem Inc | $400,000 | 1 | n/a |
| St Jude Children's Research Hospital Inc | $400,000 | 2 | 0% |
| Children's Hospital Medical Center | $367,814 | 2 | 0% |
| Cancer Research Institute Inc | $351,000 | 1 | 1% |
| Regents of the University of California at San Diego | $330,000 | 2 | n/a |
| Seven Bridges Genomics Inc | $324,000 | 1 | n/a |
| Duke University | $291,666 | 3 | 0% |
| The Broad Institute Inc | $285,240 | 1 | 0% |
| Fred Hutchinson Cancer Center | $250,000 | 2 | 0% |
| Utmd Anderson | $250,000 | 1 | n/a |
| University of Wisconsin Madison | $233,211 | 4 | n/a |
| Children's Hospital Corporation | $99,899 | 2 | 0% |
| University of North Carolina | $49,900 | 1 | n/a |
| University of Vermont | $49,500 | 1 | n/a |
| Dana-Farber Cancer Institute Inc | $49,414 | 2 | 0% |
Where it is load-bearing
Each grantee by its size and the share of its budget The Fibrolamellar Cancer Foundation supplied at peak.
Tap a dot to name the grantee.
How this is measured
Compare The Fibrolamellar Cancer Foundation with peer funders
Warm introductions · Powered by PlinthPlus
How do I get to The Fibrolamellar Cancer Foundation?
Find your warmest path to The Fibrolamellar Cancer Foundation through trustees and officers whose names appear on both boards. Search for your organization and Plinth traces the shortest route it can evidence.
Each link is a name appearing on two organizations’ public IRS 990 filings, matched on that name and, where the filings support it, on location. A same-state match has geographic support, which is a second matching feature rather than confirmation that the two are one person; a cross-state one is the likeliest to be two people who share a name. Every hop shows its tier, low-confidence and distant paths are held back rather than guessed, and it is worth confirming the person before you use the introduction.
About The Fibrolamellar Cancer Foundation
- How much does The Fibrolamellar Cancer Foundation give?
- The Fibrolamellar Cancer Foundation reported 7 itemized grants totaling $1,402,248, out of $1,654,708 in total grant expense reported on the return in its FY2024 IRS filing. It funded between 3 and 10 organizations a year over FY2017 to FY2023.
- What does The Fibrolamellar Cancer Foundation fund?
- By grant dollars over FY2017 to FY2024, its largest causes are Science & Tech (45%), Health (44%), Education (11%).
- Who are The Fibrolamellar Cancer Foundation's largest grantees?
- By total granted over FY2017 to FY2024: Dracen Pharmaceuticals Inc ($2.4M), University of Washington ($2.0M), Cornell University ($1.5M).
- Does The Fibrolamellar Cancer Foundation fund new organizations?
- In FY2023, 30% of the organizations it funded were first-time grantees.
- Where is The Fibrolamellar Cancer Foundation based?
- The Fibrolamellar Cancer Foundation is based in CT.
Play a game based on Fibrolamellar Cancer’s filings →